Another disappointing clinical trial outcome, with the immunotherapy combo durvalumab plus tremelimumab (aPDL1 + aCTLA4) failing to produce a benefit in advanced disease (ORR 3% for combination).

Treatment was well tolerated, and the efficacy of durvalumab plus tremelimumab therapy and durvalumab monotherapy reflected a population of patients with mPDAC who had poor prognoses and rapidly progressing disease. Patients were not enrolled in part B because the threshold for efficacy was not met in part A.

https://jamanetwork.com/journals/jamaoncology/article-abstract/2738420